Summers Value Partners LLC

$ALC regarding the $RXST collaboration:

With >$250 million of cash on the balance sheet and over $100 million of high margin LAL sales, $RXST looks very cheap at a $215 million market cap. Potential $ALC royalties add optionality for long term value creation.

October 28 was the deadline for $ALC to cancel the LAL collaboration with $RXST. With no 8-K indicating otherwise, the $60 million upfront payment becomes cash on RxSight's balance sheet. Alcon's commitment to the LAL program makes $RXST look very cheap.

Alcon commenting on the recently signed collaboration agreement with RxSight. The deal included a $60 million upfront payment. $ALC $RXST

BTIG to $50 on $CCSI

Follow the incentives $HALO:

$CCSI was $60 in 4Q22 vs $35 in the aftermarket today.

One week to the $ANAB vs $GSK trial in Delaware Chancery Court. Same judge as in the 2020 dispute. A settlement could be announced any day favoring $ANAB. contracts.justia.com/compani…

A settlement favoring $ANAB in the $GSK case could be announced any day. An acquisition is also possible in the $90-100 range. Going to trial will be VERY risky for $GSK. storage.courtlistener.com/pd…

Buried as an exhibit with the recently filed 10-Q, Theravance disclosed a change to a key executive's employment agreement which added a change of control provision. This could foretell a sale of the company this year. $TBPH

$HALO the perceived earnings miss caused a 9% decline in the share price today. importantly, free cash flow in the quarter set a new record at $218 million or $1.78 per share. some things matter more than others.

$CCSI could repurchase 20% of its shares this year with free cash flow over $100 million.

$CCSI expecting more buybacks in 2026.

$OTCM CEO Cromwell Coulson discussing the success of overnight trading at the SIFMA 24/7 roundtable last week. Daily overnight trading volumes are growing rapidly.

Despite free cash flow nearly doubling over the past three years, $CCSI shares remain depressed trading at a free cash flow yield of 10.9%. Balance sheet strength has improved and the company's EBITDA margin > 50%.

Congratulations to the restor3d team. Summers Value Partners participated in the financing after leading the Series A round.

$AVNS The Chairman executing the biggest insider purchase in the company's history with the stock near an all-time low.